Home / Business and Economy / Eris & Natco Forge Semaglutide Deal
Eris & Natco Forge Semaglutide Deal
24 Feb
Summary
- Eris Lifesciences partners with Natco Pharma for semaglutide commercialisation.
- Natco Pharma recently received approval to manufacture semaglutide.
- Semaglutide targets Type 2 diabetes and chronic weight management.
Eris Lifesciences has announced a strategic collaboration with Natco Pharma for the commercialization of semaglutide within India. This partnership was established shortly after Natco Pharma secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture semaglutide for the Indian market.
The approval signifies a planned launch for March 2026. Semaglutide is poised to address the growing needs in India's metabolic care sector, particularly for Type 2 diabetes management. This move comes as several Indian pharmaceutical companies prepare for the upcoming patent expiry of Semaglutide in the country next month.
Globally, semaglutide, a GLP-1 receptor agonist, has proven to be a significant advancement in treating Type 2 diabetes and chronic weight management. It is the active ingredient in widely recognized medications such as Novo Nordisk's Wegovy and Ozempic. Eris Lifesciences views this partnership as a long-term value driver, aiming to bolster its diabetes franchise with innovative therapies.
Natco Pharma will be outsourcing production to a fill-finish source for the Indian market. While the market is expected to be competitive with multiple generics, Natco is optimistic about the semaglutide launch.
